SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial
Alessandra Greco(St. Catherine University), Laura Scelsi(Policlinico San Matteo Fondazione), Giuseppina Uccello(Ospedale Garibaldi), Lorenzo Perrone(Policlinico San Matteo Fondazione), A. Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sandra Schirinzi(Policlinico San Matteo Fondazione), Stefano Ghio(Policlinico San Matteo Fondazione), Catherine Klersy(Policlinico San Matteo Fondazione), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Mauro Acquaro(St. Catherine University), Andrea Tedeschi(Guglielmo da Saliceto Hospital), M. C. Galiazzo(Policlinico San Matteo Fondazione), Maria Laura Canale(Ospedale Versilia), Annalisa Turco(Policlinico San Matteo Fondazione), M. De Amicis(Policlinico San Matteo Fondazione), Gianpiero Rizzo(Policlinico San Matteo Fondazione), L. De Luca(Policlinico San Matteo Fondazione), Fernando Guerra(Fundação Oswaldo Cruz)
Cited by 5
Related Papers
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Pulmonary Hypertension in Chronic Lung Diseases
|Journal of the American College of Cardiology|2013|683
Pulmonary Hypertension Due to Left Heart Diseases
|Journal of the American College of Cardiology|2013|635
Nutritional status in older persons according to healthcare setting: A systematic review and meta-analysis of prevalence data using MNA ®
|Clinical Nutrition|2016|487
Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
|Nature Communications|2018|395